Research programme: histone deacetylase inhibitors - CircaGenAlternative Names: Histone deacetylase inhibitors research programme - CircaGen
Latest Information Update: 04 May 2007
At a glance
- Originator CircaGen Pharmaceutical
- Mechanism of Action Histone deacetylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 May 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 27 Feb 2003 Preclinical trials in Cancer in USA (unspecified route)